Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18575164rdf:typepubmed:Citationlld:pubmed
pubmed-article:18575164lifeskim:mentionsumls-concept:C0024109lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0036202lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0022417lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C1527336lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0666743lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0034606lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0085973lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0007320lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0175668lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C0392760lld:lifeskim
pubmed-article:18575164lifeskim:mentionsumls-concept:C2347946lld:lifeskim
pubmed-article:18575164pubmed:issue2lld:pubmed
pubmed-article:18575164pubmed:dateCreated2008-6-25lld:pubmed
pubmed-article:18575164pubmed:abstractTextWe report the case of a 59 years old woman affected by lung and joint sarcoidosis, secondary Sjogren's syndrome refractory to common disease-modifying antirheumatic drugs (DMARDs) that regressed with infliximab and methotrexate. 99mTc-HYNIC-TOC scintigraphy was useful in diagnosis, choice of treatment and follow-up.lld:pubmed
pubmed-article:18575164pubmed:languageenglld:pubmed
pubmed-article:18575164pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:citationSubsetIMlld:pubmed
pubmed-article:18575164pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18575164pubmed:statusMEDLINElld:pubmed
pubmed-article:18575164pubmed:issn1128-3602lld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:MiglioreAAlld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:BizziEElld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:CapuanoAAlld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:VaccaEElld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:SignoreAAlld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:ChianelliMMlld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:TodinoVVlld:pubmed
pubmed-article:18575164pubmed:authorpubmed-author:MassafraUUlld:pubmed
pubmed-article:18575164pubmed:issnTypePrintlld:pubmed
pubmed-article:18575164pubmed:volume12lld:pubmed
pubmed-article:18575164pubmed:ownerNLMlld:pubmed
pubmed-article:18575164pubmed:authorsCompleteYlld:pubmed
pubmed-article:18575164pubmed:pagination127-30lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:meshHeadingpubmed-meshheading:18575164...lld:pubmed
pubmed-article:18575164pubmed:articleTitleRelevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report.lld:pubmed
pubmed-article:18575164pubmed:affiliationUOS of Rheumatology, Fatebenefratelli, S. Pietro Hospital, Rome, Italy. albertomigliore@terra.eslld:pubmed
pubmed-article:18575164pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18575164pubmed:publicationTypeCase Reportslld:pubmed